pharmaphorum
JANUARY 5, 2021
Tinkering with the dosing schedule of COVID-19 vaccines runs a “significant risk” to public health, the FDA has warned in a statement after the UK announced plans to prioritise the first doses of two approved shots. The regulator made its comments after the UK announced a policy of stretching the gap between doses of the vaccine to up to 12 weeks to ensure maximum coverage of vulnerable groups.
Pharma Marketing Network
JANUARY 6, 2021
Throughout the year 2020, pharma marketers were forced to explore new strategies in order to keep up with the many evolving trends. Pharma marketers have quickly learned how to adapt to these trends and are prepared to take on new opportunities in 2021. Five trends that will shape the pharma marketing industry in 2021 include media and tech, location independence, relationships despite digital congestion, questioning systems and doubt in institutions, and feelings around trust and wellness.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Druggist
JANUARY 4, 2021
Amoxicillin is the most commonly prescribed antibiotic in the UK, with over 6 mln prescriptions issued in the last 12 months. Flucloxacillin is less popular with around 3.6 mln prescriptions issued during the same time (OpenPrescribing.net, 2021). Both antibiotics’ distinct popularity comes mainly from different recommended use in the treatment of bacterial infections, even though both drugs belong to the same class of antibiotics: penicillins.
Outsourcing Pharma
JANUARY 5, 2021
Industry organizations with hires, promotions, acquisitions and other news to share this month include Parexel, Novartis, WCG, Idifarma and more top firms.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
JANUARY 8, 2021
The Pfizer/BioNTech vaccine appears to work against an important mutation in the new coronavirus variants causing havoc in the UK and South Africa, according to research from the drugs giant. Findings of the lab study posted online have not yet been peer reviewed but provide some reassurance for countries like the UK, which are relying on vaccines to bring the pandemic under control.
Pharma Times
JANUARY 4, 2021
KRAS mutations are found in several hard-to-treat cancers
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Outsourcing Pharma
JANUARY 7, 2021
A leader from the chemical manufacturing firm notes pharma companies are showing increased interest in contracting out their manufacturing functions.
pharmaphorum
JANUARY 6, 2021
Pharma companies are always talking about moving ‘beyond the pill’, and Pfizer’s new brand identity embodies that – it’s decades old pill-like logo has been replaced with a DNA double helix that it says reflects its commitment to breakthrough science. The logo – which retains the company’s traditional blue colour scheme – has been more than 18 months in the making and according to the company it is “unlocking the pill to reveal Pfizer’s DNA: the power of science.”.
Pharma Times
JANUARY 4, 2021
Shot was approved by MHRA on 30 December
Pharma Mirror
JANUARY 6, 2021
Infant nutrition, outside of breastfeeding, has become a hot topic recently. Families are taking a hard look at how baby formulas’ ingredients impact their children’s health and development. Concerns and Contamination Every day American parents and caregivers reach for over-the-counter baby formulas and are surprised to find chemicals, additives, and other ingredients that are known to cause health concerns.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Outsourcing Pharma
JANUARY 4, 2021
As healthcare providers and other high-priority patients begin receiving the vaccines, the agency continues to act to help the national pandemic response.
pharmaphorum
JANUARY 4, 2021
The pandemic has shed light on inefficiencies in healthcare systems, and provided an opportunity to adjust how we manage care in the future. Jennifer Haas, executive vice president of Noteworth, shares her 2021 predictions surrounding the future of telehealth and big data. . Healthcare providers are grappling with the task of scaling digital care delivery operations for ambulatory patients in response to the cost dynamics of effectively treating large populations with limited resources, especial
Pharma Times
JANUARY 4, 2021
Submission based on results from phase I CHRYSALIS study
Med Ed 101
JANUARY 6, 2021
Looking at the adverse effect profile of second-generation antipsychotics is critical to medication selection in clinical practice. You should definitely know the general list of adverse effects of antipsychotics (i.e. EPS, metabolic syndrome, QTc prolongation, etc.). What you should also be aware of is the subtleties for each individual agent. For ziprasidone, I remember two […].
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Outsourcing Pharma
JANUARY 7, 2021
An executive with the clinical research tech firm explains that while such studies can be rife with problems, the right approach can yield results.
pharmaphorum
JANUARY 7, 2021
Gilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch of cell therapy products for solid tumours and blood cancers. The partnership covers up to five oncology targets identified by OBT using its discovery platform, and the UK firm will try to develop antibodies against them. Kite and Gilead will then develop and commercialise therapies based on these targets or antibodies.
Pharma Times
JANUARY 5, 2021
Company is aiming for approval in the adjuvant setting
Med Ed 101
JANUARY 3, 2021
The GLP-1 Agonists have grown significantly in their popularity and there are good reasons for that increase in use. They promote weight loss which is a big problem in the majority of our type 2 diabetes patients. In addition to this benefit, they have also been shown to positively affect cardiovascular outcomes. With any medication, […]. The post GLP-1 Agonists And The Prescribing Cascade appeared first on Med Ed 101.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Outsourcing Pharma
JANUARY 7, 2021
The two organizations will collaborate on development of synthetic arms for clinical studies, drawing from millions of patient records and trial subject.
pharmaphorum
JANUARY 8, 2021
How can pharma improve the patient-centricity of its trials during COVID-19 and beyond? Experts from across the sector give their thoughts on the key approaches and technologies that are driving patient engagement forward. With COVID-19 presenting new barriers to running and recruiting for clinical trials, making studies patient-centric is more important now than ever before.
Pharma Times
JANUARY 5, 2021
New Innovative Licensing and Access Pathway launched
pharmaphorum
JANUARY 8, 2021
Six months after rebranding from BHE, Panalgo has won a contract to supply the European Medicines Agency (EMA) with its IHD data analytics platform, pledging to streamline its public health efforts. IHD – or Instant Health Data – will be used by the EMA to carry out data analyses and examine medicinal product utilisation, answer questions about safety and efficacy, and understand how treatments perform in real-world settings, said the Boston, US-based company.
pharmaphorum
JANUARY 8, 2021
New data means that IL-6 drugs from Roche and Sanofi that had been all-but written off as coronavirus therapies will now be offered routinely to COVID-19 patients in intensive care in the UK. The renaissance of the two therapies comes on the back of the REMAP-CAP trial, which found that the IL-6 inhibitors RoActemra (tocilizumab) and Kevzara (sarilumab) reduced the relative risk of death by 24% when administered to COVID-19 patients within 24 hours of entering intensive care, and reduce the tim
pharmaphorum
JANUARY 8, 2021
The global pandemic has caused pharma companies to invest in digital marketing, as healthcare systems across the world adapt to strict lockdown rules. Once the global emergency ends, this trend will continue, argues pharmaphorum’s Richard Staines. The global outbreak of COVID-19 has forced businesses to radically change their way of working. Healthcare companies have been in the vanguard of this change, with an enormous rise in the use of telehealth and all forms of digital communications.
pharmaphorum
JANUARY 7, 2021
AbbVie is in a race against time as US patent expiry of its Humira inflammatory diseases blockbuster looms in 2023 – but it just scored two crucial phase 3 trial victories that could help rebuild sales when cheaper biosimilars flood the market in two years’ time. The company’s follow-up drug Skyrizi is a key plank in AbbVie’s strategy to negotiate the $20 billion patent cliff from Humira, which has already seen sales decline outside of the US where it has already lost protection from cheaper com
pharmaphorum
JANUARY 4, 2021
In the past, sponsors submitting to FDA were required to submit a PDF describing their submission datasets. As we all know PDF is great for viewing on-screen or printing, but the information inside can’t be interpreted by a computer. Enter CDISC’s Define-XML model. Define-XML standardizes how to describe datasets in a machine-readable manner.
pharmaphorum
JANUARY 4, 2021
Roche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody showed comparable results in diabetic macular oedema (DME) but with half the injections, in twin phase 3 studies. While Eylea (aflibercept) is taken in doses eight weeks apart, results from the YOSEMITE and RHINE studies showed faricimab produces a similar effect but with a 16-week dosing regimen.
pharmaphorum
JANUARY 5, 2021
Former joint founder and owner of Resolute Communications and Real Science Paul Blackburn has launched a new hybrid agency, Certain Health. Blackburn made the move after Resolute and Real Science were absorbed into Publicis Langland. The company said its hybrid model has the benefits of both the traditional and virtual agency models, with expertise in health PR, medical education and the creative space.
pharmaphorum
JANUARY 7, 2021
Research from a large-scale survey of 1000+ senior pharma professionals has highlighted the divide between digitally adept companies and those that have been slow to adopt technologies. We look at how the customer experience is changing due to COVID-19. Historically, pharma has lagged behind other industries in adopting digital solutions, but with COVID-19 catapulting the sector, and healthcare in general, into a new digital era, the landscape is changing significantly and rapidly.
pharmaphorum
JANUARY 5, 2021
Biotech Clene Nanomedicine has gone public with a mission to use nanotherapeutics that will use gold to treat devastating neurological diseases including Parkinson’s disease. Over the Christmas period Clene closed a reverse merger with Tottenham Acquisition I Limited, allowing shares to be publicly traded on the Nasdaq stock exchange. The US-based company says it aims to revolutionise treatment of diseases including multiple sclerosis and amyotrophic lateral sclerosis with a new class of drugs t
pharmaphorum
JANUARY 5, 2021
Haven, the healthcare venture launched by Amazon, Berkshire Hathaway and JP Morgan Chase is to cease trading next month after failing to achieve its goal of pushing down health insurance costs for US workers. The joint venture had been billed by many as Amazon’s big move into healthcare when it was launched three years ago with great fanfare. But since then there has been little news from the secretive venture sparked by an idea from JPMorgan CEO Jamie Dillion, with support from Amazon’s Jeff Be
pharmaphorum
JANUARY 4, 2021
There are hopes that a new app based on blockchain technology will allow safe international travel via Singapore’s Changi Airport, which verifies passengers’ COVID-19 status before boarding planes. Developed by health and security provider International SOS and AOKPass, the app was first used to provide a digitally verifiable COVID-19 heath certificate for entrance to Singapore on 21st December.
pharmaphorum
JANUARY 6, 2021
Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometabolic diseases. Danish drugmaker Novo Nordisk signed a deal with the US biotech in 2019 valued at up to $675.5 million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 dia
Expert insights. Personalized for you.
126 
Let's personalize your content